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Background
Despite declines in morbidity and mortality with the use of combination antiretro-
viral therapy, its effectiveness is limited by adverse events, problems with adherence, 
and resistance of the human immunodeficiency virus (HIV).
Methods
We randomly assigned persons infected with HIV who had a CD4+ cell count of more 
than 350 per cubic millimeter to the continuous use of antiretroviral therapy (the 
viral suppression group) or the episodic use of antiretroviral therapy (the drug con-
servation group). Episodic use involved the deferral of therapy until the CD4+ count 
decreased to less than 250 per cubic millimeter and then the use of therapy until 
the CD4+ count increased to more than 350 per cubic millimeter. The primary end 
point was the development of an opportunistic disease or death from any cause. An 
important secondary end point was major cardiovascular, renal, or hepatic disease.
Results
A total of 5472 participants (2720 assigned to drug conservation and 2752 to viral 
suppression) were followed for an average of 16 months before the protocol was 
modified for the drug conservation group. At baseline, the median and nadir CD4+ 
counts were 597 per cubic millimeter and 250 per cubic millimeter, respectively, 
and 71.7% of participants had plasma HIV RNA levels of 400 copies or less per mil-
liliter. Opportunistic disease or death from any cause occurred in 120 participants 
(3.3 events per 100 person-years) in the drug conservation group and 47 participants 
(1.3 per 100 person-years) in the viral suppression group (hazard ratio for the drug 
conservation group vs. the viral suppression group, 2.6; 95% confidence interval [CI], 
1.9 to 3.7; P<0.001). Hazard ratios for death from any cause and for major cardio-
vascular, renal, and hepatic disease were 1.8 (95% CI, 1.2 to 2.9; P = 0.007) and 1.7 
(95% CI, 1.1 to 2.5; P = 0.009), respectively. Adjustment for the latest CD4+ count 
and HIV RNA level (as time-updated covariates) reduced the hazard ratio for the 
primary end point from 2.6 to 1.5 (95% CI, 1.0 to 2.1).
Conclusions
Episodic antiretroviral therapy guided by the CD4+ count, as used in our study, 
significantly increased the risk of opportunistic disease or death from any cause, 
as compared with continuous antiretroviral therapy, largely as a consequence of 
lowering the CD4+ cell count and increasing the viral load. Episodic antiretroviral 
therapy does not reduce the risk of adverse events that have been associated with 
antiretroviral therapy. (ClinicalTrials.gov number, NCT00027352.)
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With the advent of potent combi-nation antiretroviral therapy came the hope that such therapy might lead to 
the eradication of infection with the human im-
munodeficiency virus (HIV).1 It was soon recog-
nized, however, that this goal was unlikely to be 
achieved owing to the existence of latent reser-
voirs; people infected with HIV would need to re-
ceive antiretroviral therapy for many years, if not 
for life.2,3 Potent antiretroviral therapy is associ-
ated with substantial benefits with regard to mor-
bidity and mortality.4-6 However, the therapy is also 
associated with both short-term and long-term 
adverse events.7,8 Major metabolic and cardiovas-
cular complications have been a particular con-
cern.9,10 In addition, HIV can become resistant to 
available antiretroviral therapy, particularly if ad-
herence is poor, which can lead to cross-resistance 
within a class of drugs and, ultimately, to multi-
drug resistance.11 Prolonged use of antiretroviral 
therapy is also expensive.12
The inherent risks and problems associated 
with lifelong antiretroviral therapy have led to the 
study of treatment-sparing strategies that might 
provide the benefits of antiretroviral therapy while 
minimizing the risk of adverse events and other 
risks associated with long-term use. We conduct ed 
the Strategies for Management of Antiretroviral 
Therapy (SMART) trial in order to compare a treat-
ment strategy of episodic use of antiretroviral 
therapy according to the CD4+ count with the cur-
rent practice of continuous antiretroviral therapy.
Me thods
The SMART study was initiated by the Terry Beirn 
Community Programs for Clinical Research on 
the Acquired Immunodeficiency Syndrome (AIDS) 
and implemented in collaboration with regional 
coordinating centers in Copenhagen (the Copen-
hagen HIV Programme), London (the Clinical Tri-
als Unit of the Medical Research Council), and 
Sydney (the National Centre in HIV Epidemiology 
and Clinical Research). Some members of the 
SMART writing group developed the study proto-
col with the sponsor, the Division of AIDS of the 
National Institute of Allergy and Infectious Dis-
eases (NIAID). The writing group takes full re-
sponsibility for the completeness and veracity of 
the data, data analyses, and this article. Drugs 
used in the study were purchased by patients ei-
ther directly or through insurance, Social Secu-
rity, or public access programs.
Participants
Persons infected with HIV who were older than 
13 years and were not pregnant or breast-feeding 
were eligible for the study if their CD4+ count 
exceeded 350 cells per cubic millimeter and they 
were willing to initiate, modify, or stop antiretro-
viral therapy according to study guidelines. Partici-
pants were eligible whether or not they had received 
or were currently receiving antiretroviral therapy. 
The study was approved by the institutional review 
board at each site, and written informed consent 
was obtained from all participants.
Study Design
The SMART study is a randomized trial comparing 
two antiretroviral treatment strategies. Investi-
gators and participants were aware of the treat-
ment assignments. The viral suppression strat-
egy, which was the control strategy, was defined 
to be consistent with the 2003 guidelines for the 
use of antiretroviral agents in HIV-infected adults 
and adolescents13: available antiretroviral regi-
mens were to be used in an uninterrupted manner 
with the goal of maximal and continuous sup-
pression of HIV replication. The experimental 
drug conservation strategy entailed the episodic 
use of antiretroviral therapy according to CD4+ 
count thresholds: the use of antiretroviral ther-
apy was deferred until the CD4+ count decreased 
to less than 250 cells per cubic millimeter, at which 
time antiretroviral therapy was to be initiated (or 
reinitiated) and continued until the CD4+ count 
increased to more than 350 cells per cubic milli-
meter. The protocol also permitted antiretroviral 
therapy to be initiated (or reinitiated) if symptoms 
of disease from HIV infection (e.g., oral thrush) 
developed or the percentage of CD4+ lympho-
cytes (CD4+ percentage) was less than 15%. On 
confirmation that the CD4+ count was more than 
350 cells per cubic millimeter, antiretroviral ther-
apy was to be stopped and then resumed when 
the CD4+ count was less than 250 cells per cubic 
millimeter. During periods of antiretroviral ther-
apy, the goal was to achieve maximal viral sup-
pression. The CD4+ count thresholds for stopping 
and starting antiretroviral therapy were chosen on 
the basis of reported associations between CD4+ 
counts and the risks of opportunistic diseases 
and death.13-16
The primary end point was new or recurrent 
opportunistic disease or death from any cause. 
Qualifying clinical events included those in the 
revised case definition for AIDS of the Centers for 
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Disease Control and Prevention,17 as well as ad-
ditional conditions related to immunodeficiency 
(see the Supplementary Appendix, available with 
the full text of this article at www.nejm.org). 
Important secondary end points included death 
from any cause; serious opportunistic disease18; 
major cardiovascular, renal, or hepatic disease (see 
the Supplementary Appendix); and grade 4 adverse 
events (not including opportunistic disease) or 
death from any cause. Grade 4 adverse events were 
defined as potentially life-threatening symptom-
atic events requiring medical intervention, accord-
ing to the toxicity table of the Division of AIDS 
of the NIAID. Data on lower-grade toxic effects 
were not collected.
Using preestablished criteria, an end-point re-
view committee that was unaware of the treat-
ment assignments reviewed the events classified 
as opportunistic disease, death from any cause, 
or major cardiovascular, hepatic, or renal disease. 
The end-point review committee classified the 
underlying cause of death using the Coding of 
Death in HIV (CoDe) project system.19 Opportu-
nistic disease and major cardiovascular, renal, or 
hepatic diseases classified as confirmed or prob-
able by the end-point review committee were con-
sidered end points, as were all deaths, irrespective 
of the cause.
We calculated that 6000 patients would need 
to be enrolled for the study to have a statistical 
power of 80% to detect a 17% relative reduction 
in the rate of opportunistic disease or death from 
any cause in the drug conservation group as com-
pared with the viral suppression group, with a 
two-sided alpha level of 0.05. Follow-up was to 
continue until 910 primary end points had oc-
curred (estimated to be at least 6 years for each 
participant), assuming an event rate in the viral 
suppression group of 1.3% in each of the first 
2 years and 2.6% per year thereafter.20 Ran-
domization was stratified according to clinical 
site with the use of permuted blocks of random 
sizes.
Data Collection and Follow-up
Before randomization, participants’ antiretroviral 
therapy history and medical history were obtained, 
as were the nadir CD4+ count; the highest re-
corded plasma HIV RNA level; the CD4+ count, 
CD4+ percentage, and HIV RNA level at baseline; 
and the three most recent CD4+ counts, CD4+ 
percentages, and HIV RNA levels before baseline. 
Follow-up visits were scheduled at 1 month and 
2 months, every 2 months thereafter for the first 
year, and every 4 months in the second and sub-
sequent years. At each visit, a history was taken and 
an examination conducted, and the CD4+ count 
and HIV RNA level were measured. More frequent 
assessments could be carried out if clinical care 
was required. At baseline and at each annual visit, 
a 12-lead electrocardiogram was obtained; the 
data were electronically transmitted to a reading 
center for detection of any changes indicative of 
a silent myocardial infarction.21-23
Interim Monitoring of Safety and Efficacy
An independent data and safety monitoring board 
reviewed interim analyses from the SMART study 
at least annually. According to protocol guidelines, 
the board was to consider early termination of 
the study or modification of the protocol if find-
ings concerning the primary end point (opportu-
nistic disease or death from any cause) and the 
secondary end point of major cardiovascular, re-
nal, or hepatic disease were consistent — both 
favoring the same treatment group — and there 
was clear and substantial evidence of benefit or 
harm. An O’Brien–Fleming boundary and the Lan–
DeMets spending function were used to control 
the type I error with regard to the primary end 
point.24,25
On January 10, 2006, at its sixth meeting, the 
board recommended stopping enrollment in the 
SMART trial because of a safety risk in the drug 
conservation group and because it appeared to be 
very unlikely that superiority of the drug conserva-
tion treatment would be shown. On January 11, 
2006, investigators and participants were notified 
of these findings, enrollment was stopped, and 
participants in the drug conservation group were 
advised to restart antiretroviral therapy. All partic-
ipants continued in follow-up. This article describes 
findings through the closure of enrollment.
Statistical Analysis
The drug conservation and viral suppression groups 
were compared according to the intention-to-treat 
principle. Time-to-event methods (Kaplan–Mei-
er survival curves and Cox proportional-hazards 
models) were used to compare the drug conser-
vation group and the viral suppression group with 
respect to event rates for opportunistic disease or 
death from any cause; death from any cause; seri-
ous and nonserious opportunistic disease; major 
cardiovascular, renal, or hepatic disease; and 
grade 4 events.26 Follow-up data were censored 
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either when participants were lost to follow-up 
before January 11, 2006, or on that date.
The hazard ratios for the comparison of the 
drug conservation group with the viral suppres-
sion group were estimated from Cox models with 
a single binary treatment group indicator. We 
tested the proportional-hazards assumption by 
including an interaction term between the treat-
Table 1. Baseline Characteristics of Study Participants.*
Characteristic
Drug 
Conservation 
Group 
(N = 2720)
Viral Suppression 
Group
(N = 2752)
All
(N = 5472)
Age (yr)
Median 43 44 43
Interquartile range 38–50
Female sex (%) 26.3 28.0 27.2
Race (%)†
Black 28.5 29.8 29.1
White 56.4 54.8 55.6
Other 15.1 15.4 15.3
Mode of infection with HIV (%)‡
Sexual contact
With person of same sex 51.4 48.5 49.9
With person of opposite sex 44.4 45.6 45.0
Injection-drug use 9.8 9.5 9.7
Other or unknown 7.5 8.7 8.1
CD4+ count (cells/mm3)
Median 597 597 597
Interquartile range 466–790
CD4+ nadir (cells/mm3)
Median 250 250 250
Interquartile range 155–359
HIV RNA ≤400 copies/ml (%) 71.8 71.5 71.7
Prior recorded highest HIV RNA level (log copies/ml)
Median 4.8 4.8 4.8
Interquartile range 4.2–5.3
Cardiovascular risk factor
Current smoker (%) 41.3 39.6 40.5
Diabetes (%) 7.0 7.1 7.0
Prior cardiovascular disease (%) 6.7 6.1 6.4
Blood pressure–lowering drugs (%) 19.2 18.1 18.6
Lipid-lowering drugs (%) 15.7 15.6 15.6
Total cholesterol (mg/dl)
Median 191 189 190
Interquartile range 163–220
High-density lipoprotein cholesterol (mg/dl)
Median 40 41 40
Interquartile range 33–50
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ment indicator and the log-transformed follow-up 
time.26
The primary end point was summarized for 
selected subgroups that were predefined accord-
ing to baseline characteristics. The heterogeneity 
of hazard ratio estimates for subgroups was as-
sessed by including an interaction term between 
treatment and subgroup in expanded Cox models.
Cox proportional-hazards models were used to 
assess the effects of CD4+ counts and HIV RNA 
levels as time-dependent covariates during follow-
up on the hazard ratios for opportunistic disease 
or death from any cause. Statistical analyses were 
performed with the use of SAS software, version 
8.2. All reported P values are two-sided and have 
not been adjusted for multiple examinations of 
the data.
R esult s
Baseline Characteristics
Between January 8, 2002, and January 11, 2006, 
5472 participants were randomly assigned to treat-
ment groups (2720 to the drug conservation group 
and 2752 to the viral suppression group). Partici-
pants were enrolled at 318 sites in 33 countries. 
Table 1 summarizes key baseline characteristics. 
The treatment groups were well balanced at entry.
Follow-up
Total follow-up time was approximately 3700 
person-years in each group, with a mean follow-
up time of 16 months. Approximately 26% of par-
ticipants were followed for more than 2 years. 
Participants attended 96.5% of follow-up visits in 
Table 1. (Continued.)
Characteristic
Drug 
Conservation 
Group
(N = 2720)
Viral Suppression 
Group
(N = 2752)
All
(N = 5472)
History of ART (%)
Never received ART 4.4 4.8 4.6
Previous PI use 69.5 67.7 68.6
Previous NNRTI use 64.7 63.9 64.3
Use of ART at baseline 84.3 83.6 83.9
Time since first ART (yr)
Median 6 6 6
Interquartile range 3–8
Type of ART at baseline (% of patients receiving ART)
PI 45.1 45.2 45.2
NNRTI 50.0 47.9 49.0
PI and NNRTI 6.3 5.3 5.8
Most common drug combinations
Zidovudine, lamivudine, efavirenz 10.3 9.9 10.0
Zidovudine, lamivudine, nevirapine 7.4 7.7 7.5
Zidovudine, lamivudine, abacavir 6.5 7.1 6.8
Zidovudine, lamivudine, nelfinavir 4.6 3.9 4.3
Prior AIDS-related illness (%) 24.7 23.1 23.9
Hepatitis B (%) 2.4 2.2 2.3
Hepatitis C (%) 15.3 14.4 14.8
* None of the characteristics differed significantly between treatment groups. To convert values for cholesterol to milli-
moles per liter, multiply by 0.02586. Percentages may not total 100 because of rounding. ART denotes antiretroviral 
therapy, PI protease inhibitor, and NNRTI nonnucleoside reverse-transcriptase inhibitor.
† Race was self-reported.
‡ Mode of infection was self-reported. Percentages do not total 100 because some participants reported more than 
one mode.
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the drug conservation group and 94.8% of follow-
up visits in the viral suppression group. On Janu-
ary 11, 2006, the status with regard to the pri-
mary end point was unknown for 32 participants 
(1.2%) in the drug conservation group and 41 
participants (1.5%) in the viral suppression group 
(Fig. I in the Supplementary Appendix).
Use of Antiretroviral Therapy and Changes 
in CD4+ and HIV RNA Levels
After randomization, the median duration of the 
first period of interruption of antiretroviral ther-
apy for participants in the drug conservation group 
was 16.8 months (interquartile range, 5.7 to 42.3) 
(Fig. IIA in the Supplementary Appendix shows 
the percentage of participants who received anti-
retroviral therapy through follow-up). A total of 
343 participants stopped antiretroviral therapy a 
second time, and 62 participants stopped three 
or more times. The average CD4+ count decreased 
by 87 cells per cubic millimeter per month during 
the first 2 months after randomization among 
participants in the drug conservation group (Fig. 
IIB in the Supplementary Appendix); thereafter, 
it continued to decline but at a lower rate. On aver-
age, throughout follow-up, the CD4+ count was 
206 cells per cubic millimeter lower in the drug 
conservation group than in the viral suppression 
group. HIV RNA levels also changed rapidly in the 
drug conservation group after randomization: 
within 2 months, the percentage of participants 
with HIV RNA levels of 400 copies per milliliter 
or less decreased from 71.8% to 6.0% (Fig. IIC in 
the Supplementary Appendix). After reinitiation 
of antiretroviral therapy in the drug conservation 
group, the median time to an HIV RNA level of 
400 copies per milliliter or less was 3.1 months 
(Fig. IIIA in the Supplementary Appendix); the 
CD4+ count increased by an average of 166 cells 
per cubic millimeter within 8 months (Fig. IIIB 
in the Supplementary Appendix).
On average, participants in the drug conser-
vation group and the viral suppression group re-
ceived antiretroviral therapy during 33.4% and 
93.7% of the follow-up time, respectively. Partici-
pants in both groups had CD4+ counts of 350 
cells per cubic millimeter or more during the ma-
jority of the follow-up time (67.9% of the time in 
the drug conservation group and 92.7% of the 
time in the viral suppression group) (Fig. 1). Par-
ticipants in the drug conservation group had 
CD4+ counts of less than 250 cells per cubic mil-
limeter during 8.6% of the follow-up time, as 
compared with 1.8% of the time in the viral sup-
pression group. The percentage of follow-up time 
during which participants had HIV RNA levels 
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Figure 1. Percentage of Follow-up Time during Which Participants Had a Specified CD4+ Count and HIV RNA Level.
For 28.8% of the 3666 person-years of follow-up in the drug conservation group (Panel A), the HIV RNA level was 
400 copies per milliliter or less. Patients received antiretroviral therapy during 33% of the follow-up time. For 72.3% 
of the 3701 person-years of follow-up in the viral suppression group (Panel B), the HIV RNA level was 400 copies 
per milliliter or less. Patients received antiretroviral therapy during 94% of the follow-up time. 
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of 400 copies per milliliter or less was substan-
tially greater in the viral suppression group than 
in the drug conservation group (72.3% and 28.8%, 
respectively).
Primary End Point and Its Components
There were 120 participants in the drug conserva-
tion group and 47 in the viral suppression group 
who had an opportunistic disease or died from 
any cause (Table 2). The cumulative probabilities 
of opportunistic disease or death from any cause 
after 12, 24, and 36 months were 0.030, 0.067, and 
0.091 in the drug conservation group and 0.010, 
0.021, and 0.042 in the viral suppression group, 
respectively (Fig. 2A).
The estimated hazard ratio for opportunistic 
disease or death from any cause was 2.6 (95% 
confidence interval [CI], 1.9 to 3.7; P<0.001) 
(Table 2 and Fig. 2A), and it did not vary signifi-
cantly over the follow-up period (P = 0.78 for pro-
portional hazards). Among patients in the drug 
conservation group who reached the primary end 
point, death from any cause was the most com-
mon individual event (39.2%), followed by esoph-
ageal candidiasis (20.0%) and pneumonia from 
Pneumocystis jiroveci infection (6.7%). Among pa-
tients in the viral suppression group who reached 
the primary end point, the most common event 
was death from any cause (57.4%), followed by 
esophageal candidiasis (14.9%) (Table I in the 
Supplementary Appendix).
The estimated hazard ratio for serious oppor-
tunistic disease, a component of the primary end 
point, was 6.6 (95% CI, 1.5 to 29.1; P = 0.01); the 
hazard ratio for nonserious events associated with 
opportunistic disease was 3.6 (95% CI, 2.1 to 6.1; 
P<0.001); and the hazard ratio for death from any 
cause was 1.8 (95% CI, 1.2 to 2.9; P = 0.007) (Ta-
ble 2 and Fig. 2B).
Only 8% of deaths were due to opportunistic 
disease. The most common underlying causes of 
death were cancers other than those considered 
to be opportunistic disease (in 11 participants in 
the drug conservation group and 5 participants in 
the viral suppression group); cardiovascular dis-
ease (7 participants and 4 participants, respec-
tively); substance abuse (3 participants and 5 par-
ticipants, respectively); accident, violence, or suicide 
(3 participants and 4 participants, respectively); 
and infection other than that considered to be 
Table 2. Primary and Major Secondary End Points.*
End Point
Drug Conservation Group 
(N = 2720)
Viral Suppression Group 
(N = 2752)
Hazard Ratio for 
Drug Conservation 
Group vs. Viral 
Suppression Group 
(95% CI) P Value
No. of Participants 
with Event
Event Rate 
(per 100 Person-Yr)
No. of Participants 
with Event
Event Rate 
(per 100 Person-Yr)
Primary end point 120 3.3 47 1.3 2.6 (1.9–3.7) <0.001
Death from any cause 55 1.5 30 0.8 1.8 (1.2–2.9) 0.007
Opportunistic disease
Serious 13 0.4 2 0.1 6.6 (1.5–29.1) 0.01
Nonserious 63 1.7 18 0.5 3.6 (2.1–6.1) <0.001
Major cardiovascular, renal, 
or hepatic disease
65 1.8 39 1.1 1.7 (1.1–2.5) 0.009
Fatal or nonfatal cardio-
vascular disease
48 1.3 31 0.8 1.6 (1.0–2.5) 0.05
Fatal or nonfatal renal 
disease
9 0.2 2 0.1 4.5 (1.0–20.9) 0.05
Fatal or nonfatal liver 
disease
10 0.3 7 0.2 1.4 (0.6–3.8) 0.46
Grade 4 event 173 5.0 148 4.2 1.2 (1.0–1.5) 0.13
Grade 4 event or death from 
any cause
205 5.9 164 4.7 1.3 (1.0–1.6) 0.03
* Numbers of individual events of each type do not sum to the total number because some participants had more than one event. End-point 
definitions are listed in the Supplementary Appendix. Grade 4 events were determined on the basis of toxicity grades developed by the 
Division of AIDS of the NIAID. CI denotes confidence interval.
The New England Journal of Medicine 
Downloaded from nejm.org at UQ Library on July 5, 2017. For personal use only. No other uses without permission. 
 Copyright © 2006 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ng l a nd  j o u r na l  o f  m e dic i n e
n engl j med 355;22 www.nejm.org november 30, 20062290
an opportunistic disease (3 participants and 1 par-
ticipant, respectively). For 18 participants who 
died (15 in the drug conservation group and 3 in 
the viral suppression group), the underlying cause 
of death could not be determined (Table II in the 
Supplementary Appendix).
We examined the robustness of the primary 
end-point findings by considering three addition-
al outcomes: opportunistic diseases (restricted to 
those that were new [nonrecurrent]) or death from 
any cause; fatal and nonfatal cases of opportu-
nistic disease (excluding deaths from causes other 
than opportunistic disease); and all report ed cases 
of opportunistic diseases and deaths ir respective 
of the classification after review by the end-point 
review committee. The estimated hazard ratios 
for these three outcomes in the drug conservation 
group versus the viral suppression group were 
2.6 (95% CI, 1.8 to 3.7; P<0.001), 3.6 (95% CI, 
2.2 to 5.9; P<0.001), and 2.5 (95% CI, 1.9 to 3.3; 
P<0.001), respectively.
Major Cardiovascular, Renal, 
and Hepatic Disease
Among the participants in the drug conservation 
group, 65 had at least one episode of major car-
diovascular, renal, or hepatic disease, as did 39 
participants in the viral suppression group (haz-
ard ratio, 1.7; 95% CI, 1.1 to 2.5; P = 0.009) (Table 
2 and Fig. 2C). Estimated hazard ratios for each 
type of disease were all greater than 1.0, favoring 
the viral suppression group.
Grade 4 Events
Grade 4 adverse symptomatic events occurred in 
173 participants in the drug conservation group 
and 148 participants in the viral suppression group 
(hazard ratio, 1.2; 95% CI, 1.0 to 1.5; P = 0.13) 
(Table 2 and Fig. 2D, and Table III in the Supple-
mentary Appendix). The hazard ratio for the com-
posite outcome of a grade 4 event or death from 
any cause was 1.3 (95% CI, 1.0 to 1.6; P = 0.03).
Primary End Point According to Subgroup
Estimated hazard ratios varied significantly ac-
cording to race, baseline HIV RNA level, and 
baseline CD4+ cell count (Fig. 3). Among partici-
pants who were receiving antiretroviral therapy 
at baseline, for those with an HIV RNA level of 
400 copies per milliliter or less at baseline, the 
hazard ratio for opportunistic disease or death 
from any cause was 4.0, whereas those with levels 
of more than 400 copies per milliliter had a haz-
ard ratio of 1.2 (P<0.001). This significant differ-
ence was due to different rates of opportunistic 
disease or death from any cause in the viral sup-
pression group between the subgroups with HIV 
RNA levels of 400 copies per milliliter or less and 
those with HIV RNA levels of more than 400 cop-
ies per milliliter (0.8 and 2.6 events per 100 person-
years, respectively), in contrast to similar rates for 
those subgroups in the drug conservation group 
(3.2 and 3.1, respectively).
Adjustment for Latest CD4+ Count 
and HIV RNA Level
Proportional-hazards models were used to assess 
the effects of time-dependent covariates corre-
sponding to the latest CD4+ counts and latest HIV 
RNA levels, considered separately and together, 
on the hazard ratio (Fig. 4). The hazard ratio for 
opportunistic disease or death from any cause 
was reduced from 2.6 to 1.7 (95% CI, 1.2 to 2.5) 
after adjustment for the latest CD4+ count; it was 
further reduced to 1.5 (95% CI, 1.0 to 2.1) after 
adjustment for both the latest HIV RNA level and 
the latest CD4+ count. Adjusted for both the lat-
est HIV RNA level and the latest CD4+ count, the 
hazard ratios for opportunistic disease and for 
death from causes other than opportunistic dis-
ease were 1.7 (95% CI, 1.0 to 2.9) and 1.2 (95% CI, 
0.7 to 2.2), respectively; unadjusted, these hazard 
ratios were 3.6 (95% CI, 2.2 to 5.9) for opportu-
nistic disease and 1.8 (95% CI, 1.1 to 2.9) for 
death from causes other than opportunistic dis-
ease, respectively.
Discussion
Our data demonstrate that continuous use of anti-
retroviral therapy is superior to its episodic use 
as guided by the CD4+ count, with antiretroviral 
therapy deferred until the CD4+ count is less than 
250 cells per cubic millimeter. The superiority of 
the viral suppression strategy, designed to achieve 
Figure 2 (facing page). Cumulative Probability of the 
Primary End Point (Panel A); Death from Any Cause 
(Panel B); Major Cardiovascular, Renal, or Hepatic 
 Disease (Panel C); and Grade 4 Adverse Events (Panel D).
Grade 4 adverse events were determined on the basis 
of toxicity grades developed by the Division of AIDS of 
the NIAID. End-point definitions are listed in the Sup-
plementary Appendix.
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maximal and continuous suppression of HIV rep-
lication with the use of antiretroviral therapy, was 
evident with regard to the primary end point (op-
portunistic disease or death from any cause), as 
well as death from any cause, serious opportunis-
tic disease, and an important secondary end point, 
major cardiovascular, renal, or hepatic disease.
Interruption of antiretroviral therapy has been 
advocated as a treatment strategy to enhance the 
quality of life, limit adverse events, and allow for 
the emergence of the predominant wild-type 
virus in patients infected with multidrug-resistant 
HIV.27,28 Two randomized studies have used high-
er CD4+ count thresholds than those used in our 
study for the initiation of antiretroviral therapy, 
but they involved only 69 patients29 and 74 pa-
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Figure 3. Hazard Ratios for Opportunistic Disease or Death from Any Cause. 
The dashed line represents the overall hazard ratio (drug conservation group vs. viral suppression group) of 2.6. Horizontal lines indi-
cate 95% CIs. Subgroup data for HIV RNA levels were restricted to participants who were receiving antiretroviral therapy at baseline. Race 
was self-reported. ART denotes antiretroviral therapy.
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tients30,31 and were therefore too small to allow 
for the reliable assessment of effects of treatment 
interruption on clinical outcomes.
More recently, the findings of two other larger, 
randomized trials were reported. In the Staccato 
study, in which the primary end point was viro-
logic suppression and the amount of exposure to 
antiretroviral drugs, 284 patients were randomly 
assigned to receive antiretroviral therapy guided 
by the CD4+ count (with therapy deferred until 
the CD4+ count was less than 350 cells per cubic 
millimeter and then used until the CD4+ count 
was more than 350 cells per cubic millimeter) and 
146 patients were randomly assigned to receive 
continuous antiretroviral therapy.32 After approxi-
mately 2 years of follow-up, diarrhea and neuropa-
thy were more common among those receiving 
continuous therapy, and oral and vaginal candi-
diasis were more common among those receiv-
ing episodic therapy. In the Trivacan study, 216 
patients were randomly assigned to episodic ther-
apy with the same CD4+ count thresholds as those 
in our study, and 110 patients were randomly as-
signed to continuous antiretroviral therapy.33 An 
increased risk of bacterial infections and other 
complications were noted in the episodic treat-
ment group.
When we began our study, data indicated that 
the risk of AIDS was low among patients who 
had never received antiretroviral therapy and 
among those who had received it but who also 
had CD4+ counts of more than 200 cells per 
cubic millimeter.14-16 Consequently, we chose to 
use a CD4+ count threshold of 250 cells per cubic 
millimeter for initiation (or reinitiation) of anti-
retroviral therapy in the drug conservation group, 
and CD4+ counts and symptoms were monitored 
closely. Data also indicated that complications 
and deaths among patients with higher CD4+ 
levels were largely due to grade 4 adverse events 
and deaths from causes other than opportunistic 
disease that were either associated with antiret-
roviral therapy or attributable to non-HIV causes.8 
Thus, we expected the risk of death from causes 
other than opportunistic disease to decrease with 
the interruption of antiretroviral therapy, rather 
than to increase.
In our study, deaths represented a large per-
centage of the primary events (44.3%) and, as in 
other reports, deaths from causes other than op-
portunistic disease were common.8,34-36 The ex-
cess of deaths from causes other than opportu-
nistic disease in the drug conservation group was 
surprising. Furthermore, contrary to available data 
and to the assumptions underlying our study de-
sign, participants in the drug conservation group 
had a higher rate of major cardiovascular, renal, 
or hepatic disease than did those in the viral sup-
pression group. On the basis of prior findings, 
and as a consequence of less exposure to antiret-
roviral therapy in the drug conservation group,10,37 
we expected the rate of cardiovascular disease to 
be 15% lower in the drug conservation group than 
in the viral suppression group.
There were fewer occurrences of major hepatic 
or renal disease than of cardiovascular disease 
in our study, but hepatic or renal disease was still 
more frequent in the drug conservation group 
than in the viral suppression group. Some anti-
retroviral drugs have been associated with adverse 
hepatic and renal events,7,38,39 but recent find-
ings indicate that these events are also related to 
the level of immunodeficiency40,41 and that anti-
retroviral therapy improves these outcomes either 
directly by inhibiting viral replication or indirectly 
by improving immune function.39 Our data sup-
port these findings. Adjustment for the latest 
CD4+ count reduced the hazard ratio in the drug 
conservation group versus the viral suppression 
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Figure 4. Estimated Unadjusted and Adjusted Hazard Ratios (Drug Conser-
vation Group vs. Viral Suppression Group) for Opportunistic Disease 
or Death from Any Cause, Opportunistic Disease (Fatal or Nonfatal), 
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group for death from causes other than oppor-
tunistic disease, confirming that immunosup-
pression increases the risk of death among pa-
tients with diseases not traditionally believed to 
be opportunistic in nature. Much, but not all, of 
the difference in the rates of opportunistic disease 
or death from any cause between the drug con-
servation group and the viral suppression group 
was explained by differences in the CD4+ count 
and HIV RNA level during follow-up. The hazard 
ratio for opportunistic disease or death from any 
cause in the drug conservation group versus the 
viral suppression group was reduced from 2.6 to 
1.5 after adjustment for the latest CD4+ count 
and the latest HIV RNA level. The reasons for 
the remaining excess risk are not clear.
Although our findings indicate that the inter-
ruption of antiretroviral therapy with the use of 
higher CD4+ count thresholds than those used 
in our study may result in lower risks of opportu-
nistic disease or death from any cause, the lack 
of benefit of our interruption strategy on major 
adverse events associated with antiretroviral ther-
apy suggests that such strategies should be viewed 
as carrying a net clinical risk unless proven other-
wise in appropriately powered studies.
In summary, our findings provide clear and 
compelling evidence that the episodic antiretro-
viral strategy, guided by the CD4+ count, used in 
the SMART study is deleterious. Our results indi-
cate that some of the excess risk of opportunis-
tic disease or death from any cause in the drug 
conservation group appears to be attributable to 
the longer period during which participants had 
reduced CD4+ counts. Further research is needed 
to evaluate the effect of interrupting antiretrovi-
ral therapy on immune function, inflammation, 
and other markers.
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